Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

107.17
-5.3600-4.76%
Post-market: 107.170.00000.00%19:30 EDT
Volume:441.21K
Turnover:47.60M
Market Cap:7.38B
PE:-34.38
High:114.75
Open:110.21
Low:107.09
Close:112.53
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:1.13
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:71.65
PE(LYR):-34.46

Loading ...

BRIEF-Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists

Reuters
·
Jun 16

Rhythm Pharma says setmelanotide cuts BMI 18.9% at 2.5 years in hypothalamic obesity study

Reuters
·
Jun 16

Rhythm Pharmaceuticals Announces Multiple New Data Presentations From Mc4r Agonists in Acquired Hypothalamic Obesity (Ho), Bardet-Biedl Syndrome (Bbs) and Prader-Willi Syndrome (Pws) at Endo 2026

THOMSON REUTERS
·
Jun 16

Rhythm Pharmaceuticals (RYTM) Receives a Buy from Jefferies

TIPRANKS
·
Jun 15

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Rhythm Pharmaceuticals (RYTM) and Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Jun 15

Rhythm announces preliminary data from Phase 2 trial of setmelanotide

TIPRANKS
·
Jun 15

Rhythm Pharmaceuticals (RYTM) Stock After Positive Phase 2 PWS Data What Does The Valuation Suggest

Simply Wall St.
·
Jun 15

BRIEF-Rhythm Pharmaceuticals Says Six-Month Data Shows Setmelanotide Improves Multiple Endpoints In Pws

Reuters
·
Jun 13

Rhythm Pharmaceuticals - Six-Month Data Shows Setmelanotide Improves Multiple Endpoints in Pws as of May 7, 2026

THOMSON REUTERS
·
Jun 13

Rhythm Pharma to present interim six-month Phase 2 setmelanotide data in Prader-Willi syndrome on June 13

Reuters
·
Jun 13

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients With Prader-Willi Syndrome

THOMSON REUTERS
·
Jun 13

Rhythm Algorithm Aims To Clarify Bardet Biedl Diagnosis And Market Potential

Simply Wall St.
·
May 30

Rhythm Pharma hosts inaugural MOMENTUM MC4R Pathway Summit featuring updated BBS diagnostic algorithm presentation

Reuters
·
May 28

Rhythm Pharma releases corporate presentation on MC4R agonist pipeline for rare obesity disorders

Reuters
·
May 27

Rhythm Pharma CFO to speak at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 26

Rhythm Pharma Controller, CAO Christopher Paul German disposes 4,643 shares worth $428,131.03

Reuters
·
May 20

Expanded EU IMCIVREE Label for Hypothalamic Obesity Could Be A Game Changer For Rhythm (RYTM)

Simply Wall St.
·
May 16

Rhythm says setmelanotide cuts BMI 16.9% at 12 months in acquired hypothalamic obesity study

Reuters
·
May 12

Guggenheim Remains a Buy on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
May 11

iBio names Elizabeth Stoner to board as Schimmelpennink steps down

Reuters
·
May 08